Crinetics Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 176,000 shares of its common stock to fifteen new non-executive employees.

Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update


Crinetics Pharmaceuticals reported first quarter 2024 financial and provided a business update on clinical progress.

Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024


Crinetics Pharmaceuticals announced five abstracts from its clinical development programs, including four late-breaking abstracts, will be presented at the Endocrine Society’s annual meeting.

Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024


Crinetics Pharmaceuticals announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the close of the U.S. financial markets.

Crinetics Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 121,300 shares of its common stock to ten new non-executive employees